Familial hypertrophic cardiomyopathy was associated with a higher risk of cardiovascular mortality or cardiac transplantation compared to non-familial cases (P=0.0084).
Cohort (n=1,243)
No
Does familial hypertrophic cardiomyopathy increase the risk of mortality or cardiac transplantation compared to non-familial hypertrophic cardiomyopathy in patients with HCM?
1243 patients with hypertrophic cardiomyopathy (HCM), including 125 with familial HCM (FHCM), treated at a single center in China between 1996 and 2013.
Familial hypertrophic cardiomyopathy (FHCM) diagnosis
Non-familial hypertrophic cardiomyopathy (non-FHCM) diagnosis, matched 4:1 using propensity scores based on 30 demographic and clinical variables
Cardiovascular mortality or cardiac transplantationhard clinical
Familial hypertrophic cardiomyopathy is an independent prognostic predictor for cardiovascular mortality and cardiac transplantation compared to non-familial cases.
p-value: p=0.0084
ObjectivesHypertrophic cardiomyopathy (HCM) is the most common hereditary cardiomyopathy. However, few studies have investigated the prognosis of familial HCM (FHCM) through clinical data. The purpose of this study was to compare the clinical outcomes of FHCM and non-FHCM through propensity score matching analysis.Methods and resultsThe cohort study included 1243 patients with HCM between 1996 and 2013 in Fuwai Hospital, Chinese Academy of Medical Sciences, among whom 125 patients had FHCM. During a mean follow-up of 7.6 ± 3.8 years (interquartile range: (IQR) 5.0–10.0 years), 217 (16.57%) of the 1243 patients had died, including 3 patients who underwent cardiac transplantation. Using 30 demographic and clinical variables, a 4:1 propensity score matched cohort for FHCM was established. The stepwise variable selection procedure for the Cox proportional hazards model was performed to identify the factors associated with mortality and competing risk regression analysis was performed to analyze the competitive risk of cardiovascular and non-cardiovascular mortality. The results showed that FHCM patients had a higher risk of cardiovascular mortality/cardiac transplantation (log-rank χ2 = 6.8, P = 0.0084) and an increased tendency of sudden cardiac death (SCD) (log-rank χ2 = 3.2, P = 0.074) compared with non-FHCM patients, but there was no difference in all-cause mortality (log-rank χ2 = 2.7, P = 0.1) between the two groups. Moreover, the Cox model showed that FHCM was an independent prognostic predictor for cardiovascular mortality/cardiac transplantation in HCM patients.ConclusionFHCM patients had a higher risk of cardiovascular mortality/cardiac transplantation and a higher tendency of SCD than non-FHCM patients, but there was no difference in all-cause mortality. Moreover, FHCM was an independent prognostic predictor for cardiovascular mortality/cardiac transplantation in HCM patients.
Building similarity graph...
Analyzing shared references across papers
Loading...
Ye He
Shenyang Pharmaceutical University
Chaoping Yu
Chengdu Medical College
Ling Zhou
Henan Cancer Hospital
Heliyon
Chinese Academy of Medical Sciences & Peking Union Medical College
University of Electronic Science and Technology of China
Southwestern University of Finance and Economics
Building similarity graph...
Analyzing shared references across papers
Loading...
He et al. (Sun,) conducted a cohort in Hypertrophic cardiomyopathy (HCM) (n=1,243). Familial hypertrophic cardiomyopathy (FHCM) vs. Non-familial hypertrophic cardiomyopathy (non-FHCM) was evaluated on Cardiovascular mortality/cardiac transplantation (p=0.0084). Familial hypertrophic cardiomyopathy was associated with a higher risk of cardiovascular mortality or cardiac transplantation compared to non-familial cases (P=0.0084).
synapsesocial.com/papers/6a11d4d402d9c5b084219d2e — DOI: https://doi.org/10.1016/j.heliyon.2023.e17629